The enzymatic inactivation of the fatty acid amide class of signaling lipids

Chemistry and Physics of Lipids

Volumn 121, Issue 1-2, 2002, Pages 135-148

  Cravatt, Benjamin F ^a   Lichtman, Aron H ^b  

^a SCRIPPS RESEARCH INSTITUTE   (United States)

^b VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

Author keywords

Anandamide; Endocannabinoid; Fatty acid amide hydrolase; Oleamide; Pain

Indexed keywords

ANANDAMIDE; CANNABINOID; CANNABINOID RECEPTOR AGONIST; CANNABINOID RECEPTOR ANTAGONIST; DRONABINOL; FATTY ACID AMIDASE; LIPID; OLEAMIDE; RIMONABANT;

BREAST CARCINOMA; CONFERENCE PAPER; DRUG ACTIVITY; DRUG EFFECT; DRUG INHIBITION; DRUG RECEPTOR BINDING; DRUG USE; ENZYME ACTIVITY; ENZYME ANALYSIS; ENZYME DEGRADATION; ENZYME INACTIVATION; HUMAN; IN VIVO STUDY; KNOCKOUT MOUSE; NEUROPHYSIOLOGY; NOCICEPTION; NONHUMAN; PAIN; PRIORITY JOURNAL; PROTEIN FUNCTION; SPONTANEOUS ABORTION;

AMIDES; AMIDOHYDROLASES; AMINO ACID SEQUENCE; ANIMALS; ARACHIDONIC ACIDS; CANNABINOIDS; ENDOCANNABINOIDS; FATTY ACIDS; HUMANS; POLYUNSATURATED ALKAMIDES; SIGNAL TRANSDUCTION; SYNAPSES;

MAMMALIA;

EID: 0037207093     PISSN: 00093084     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-3084(02)00147-0     Document Type: Conference Paper

References (80)

1. Abadji V., Lin S., Taha G., Griffin G., Stevenson L.A., Pertwee R.G., Makriyannis A. (R)-Methanandamide: a chiral novel anandamide possessing higher potency and metabolic stability. J. Med. Chem. 37:1994;1889-1993.
2. Adams I.B., Compton D.R., Martin B.R. Assessment of anandamide interaction with the cannabinoid brain receptor: SR 141716A antagonism studies in mice and autoradiographic analysis of receptor binding in rat brain. J. Pharmacol. Exp. Ther. 284:1998;1209-1217.
3. Aumais J.P., Lee H.S., DeGannes C., Horsford J., White J.H. Function of directly repeated half-sites as response elements for steroid hormone receptors. J. Biol. Chem. 271:1996;12568-12577.
4. Basile A.S., Hanus L., Mendelson W.B. Characterization of the hypnotic properties of oleamide. Neuroreport. 10:1999;947-951.
5. Beltramo M., Stella N., Calignano A., Lin S.Y., Makriyannis A., Piomelli D. Functional role of high-affinity anandamide transport, as revealed by selective inhibition. Science. 277:1997;1094-1097.
6. Boger D.L., Sato H., Lerner A.E., Austin B.J., Patterson J.E., Patricelli M.P., Cravatt B.F. Trifluoromethyl ketone inhibitors of fatty acid amide hydrolase: a probe of structural and conformational features contributing to inhibition. Bioorg. Med. Chem. Lett. 9:1999;265-270.
7. Boger D.L., Sato H., Lerner A.E., Hedrick M.P., Fecik R.A., Miyauchi H., Wilkie G.D., Austin B.J., Patricelli M.P., Cravatt B.F. Exceptionally potent inhibitors of fatty acid amide hydrolase: the enzyme responsible for degradation of endogenous oleamide and anandamide. Proc. Natl. Acad. Sci. USA. 97:2000;5044-5049.
8. Boring D.L., Berglund B.A., Howlett A.C. Cerebrodience, arachidonylethanolamide, and hybrid structures: potential for interaction with brain cannabinoid receptor. Prostaglandins Leukotrienes. Essent. Fatty Acids. 55:1996;207-210.
9. Cadas H., di Tomaso E., Piomelli D. Occurence and biosynthesis of endogenous cannabinoid precursor, N-arachidonyl phosphatidylethanolamine, in rat brain. J. Neurosci. 17:1997;1226-1242.
10. Calignano A., La Rana G., Giuffrida A., Piomelli D. Control of pain initiation by endogenous cannabinoids. Nature. 394:1998;277-281.
11. Chanock S. Candidate genes and single nucleotide polymorphisms (SNPs) in the study of human disease. Dis. Markers. 17:2001;89-98.
12. Cravatt B.F., Prospero-Garcia O., Siuzdak G., Gilula N.B., Henriksen S.J., Boger D.L., Lerner R.A. Chemical characterization of a family of brain lipids that induce sleep. Science. 268:1995;1506-1509.
13. Cravatt B.F., Giang D.K., Mayfield S.P., Boger D.L., Lerner R.A., Gilula N.B. Molecular characterization of an enzyme that degrades neuromodulatory fatty-acid amides. Nature. 384:1996;83-87.
14. Cravatt B.F., Demarest K., Patricelli M.P., Bracey M.H., Giang D.K., Martin B.R., Lichtman A.H. Supersensitivity to anandamide and enhanced endogenous cannabinoid signaling in mice lacking fatty acid amide hydrolase. Proc. Natl. Acad. Sci. USA. 98:2001;9371-9376.
15. De Petrocellis L., Melck D., Palmisano A., Bisogno T., Laezza C., Bifulco M., Di Marzo V. The endogenous cannabinoid anandamide inhibits human breast cancer cell proliferation. Proc. Natl. Acad. Sci. USA. 95:1998;8375-8380.
16. Desarnaud F., Cadas H., Piomelli D. Anandamide amidohydrolase activity in rat brain microsomes: identification and partial characterization. J. Biol. Chem. 270:1995;6030-6035.
17. Deutsch D.G., Chin S.A. Enzymatic synthesis and degradation of anandamide, a cannabinoid receptor agonist. Biochem. Pharmacol. 46:1993;791-796.
18. Deutsch D.G., Glaser S.T., Howell J.M., Kunz J.S., Puffenbarger R.A., Hillard C.J., Abumrad N. The cellular uptake of anandamide is coupled to its breakdown by fatty acid amide hydrolase. J. Biol. Chem. 276:2001;6967-6973.
19. Deutsch D.G., Ueda N., Yamamoto S. The fatty acid amide hydrolase (FAAH). Prostaglandins Leukotrienes. Essent. Fatty Acids. 66:2002;309-317.
20. Devane W.A., Hanus L., Breur A., Pertwee R.G., Stevenson L.A., Griffin G., Gibson D., Mandelbaum A., Etinger A., Mechoulam R. Isolation and structure of a brain constituent that binds to the cannabinoid receptor. Science. 258:1992;1946-1949.
21. Di Marzo V., Fontana A., Cadas H., Schinelli S., Cimino G., Schwartz J.-C., Piomelli D. Formation and inactivation of endogenous cannabinoid anandamide in central neurons. Nature. 372:1994;686-691.
22. Di Marzo V., Breivogel C.S., Tao Q., Bridgen D.T., Razdan R.K., Zimmer A.M., Zimmer A., Martin B.R. Levels, metabolism, and pharmacological activity of anandamide in CB1 cannabinoid knockout mice: evidence for non-CB1, non-CB2 receptor-mediated actions of anandamide in the mouse brain. J. Neurochem. 75:2000;2434-2444.
23. Di Marzo V., Melck D., Orlando P., Bisogno T., Zagoory O., Bifulco M., Vogel Z., De Petrocellis L. Palmitoylethanolamide inhibits the expression of fatty acid amide hydrolase and enhances the anti-proliferative effect of anandamide in human breast cancer cells. Biochem. J. 358:2001;249-255.
24. Dinh T.P., Carpenter D., Leslie F.M., Freund T.F., Katona I., Sensi S.L., Kathuria S., Piomelli D. Brain monoglyceride lipase participating in endocannabinoid inactivation. Proc. Natl. Acad. Sci. USA. 99:2002;10819-10824.
25. Egertova M., Giang D.K., Cravatt B.F., Elphick M.R. A new perspective on cannabinoid signalling: complimentary localization of fatty acid amide hydrolase and the CB1 receptor in rat brain. Proc. R. Soc. Lond. B. 265:1998;2081-2085.
26. Federova I., Hashimoto A., Fecik R.A., Hedrick M.P., Hanus L., Boger D.L., Rice K.C., Basile A.S. Behavioral evidence for the interaction of oleamide with multiple neurotransmitter systems. J. Pharmacol. Exp. Ther. 299:2001;332-342.
27. Felder C.C., Briley E.M., Axelrod J., Simpson J.T., Mackie K., Devane W.A. Anandamide, an endogenous cannabimimetic eicosanoid, binds to the cloned human cannabinoid receptor and stimulates receptor-mediated signal transduction. Proc. Natl. Acad. Sci. USA. 90:1993;7656-7660.
28. Fowler C.J., Jonsson K.O., Tiger G. Fatty acid amide hydrolase: biochemistry, pharmacology, and therapeutic possibilities for an enzyme hydrolyzing anandamide, 2-arachidonylglycerol, palmitoylethanolamide, and oleamide. Biochem. Pharmacol. 62:2001;517-526.
29. Giang D.K., Cravatt B.F. Molecular characterization of human and mouse fatty acid amide hydrolases. Proc. Natl. Acad. Sci. USA. 94:1997;2238-2242.
30. Goparaju S.K., Kurahashi Y., Suzuki H., Ueda N., Yamamoto S. Anandamide amidohydrolase of porcine brain: cDNA cloning, functional expression and site-directed mutagenesis. Biochim. Biophys. Acta. 1441:1999;77-84.
31. Huang S., New L., Pan Z., Han J., Nemerow G.R. Urokinase plasminogen activator/urokinase-specific receptor expression and matrix invasion by breast cancer cells requires constitutive p38alpha mitogen-activated protein kinase activity. J. Biol. Chem. 275:2000;12266-12272.
32. Huidobro-Toro J.P., Harris R.A. Brain lipids that induce sleep are novel modulators of 5-hydroxytryptamine receptors. Proc. Natl. Acad. Sci. USA. 93:1996;8078-8082.
33. Huitron-Resendiz S., Gombart L., Cravatt B.F., Henriksen S.J. Effect of oleamide on sleep and its relationship to blood pressure, body temperature, and locomotor activity in rats. Exp. Neurol. 172:2001;235-243.
34. Jagger S.I., Hasnie F.S., Sellaturay S., Rice A.S.C. The anti-hyperalgesic actions of the cannabinoid anandamide and the putative CB2 receptor agonist palmitoylethanolamide in visceral and somatic inflammatory pain. Pain. 76:1998;189-199.
35. Jensen T.S. Anticonvulsants in neuropathic pain: rationale and clinical evidence. Eur. J. Pain. 6:2002;61-68.
36. Jessani N., Liu Y., Humphrey M., Cravatt B.F. Enzyme activity profiles of the secreted and membrane proteome that depict cancer cell invasiveness. Proc. Natl. Acad. Sci. USA. 99:2002;10335-10340.
37. Laposky A.D., Homanics G.E., Basile A.S., Mendelson W.B. Deletion of the GABA(A) receptor beta 3 subunit eliminates the hypnotic actions of oleamide in mice. Neuroreport. 12:2001;4143-4147.
38. Lerner R.A., Siuzdak G., Prospero-Garcia O., Henriksen S.J., Boger D.L., Cravatt B.F. Cerebrodiene: a brain lipid isolated from sleep-deprived cats. Proc. Natl. Acad. Sci. USA. 91:1994;9505-9508.
39. Lichtman A.H., Hawkins E.G., Griffin G., Cravatt B.F. Pharmacological activity of fatty acid amides is regulated, but not mediated, by fatty acid amide hydrolase in vivo. J. Pharmacol. Exp. Ther. 302:2002;73-79.
40. Maccarrone M., De Felici M., Bari M., Klinger F., Siracusa G., Finazzi-Agro A. Down-regulation of anandamide hydrolase in mouse uterus by sex hormones. Eur. J. Biochem. 267:2000;2991-2997.
41. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romanini C., Finazzi-Agro A. Relation between decreased anandamide hydrolase concentrations in human lymphocytes and miscarriage. Lancet. 355:2000;1326-1329.
42. Maccarrone M., Valensise H., Bari M., Lazzarin N., Romagnani S., Finazzi-Agro A. Progesterone up-regulates anandamide hydrolase in human lymphocytes: role of cytokines and implications for fertility. J. Immunol. 166:2001;7183-7189.
43. Maccarrone M., Bisogno T., Valensise H., Lazzarin N., Fezza F., Manna C., Di Marzo V., Finazzi-Agro A. Low fatty acid amide hydrolase and high anandamide levels are associated with a failure to achieve an ongoing pregnancy after IVF and embryo transfer. Mol. Hum. Reprod. 8:2002;188-195.
44. Maccarrone M., Falciglia K., Di Rienzo M., Finazzi-Agro A. Endocannabinoids, hormone-cytokine networks and human fertility. Prostaglandins Leukotrienes. Essent. Fatty Acids. 66:2002;309-317.
45. Maurelli S., Bisogno T., De Petrocellis L., Di Luccia A., Marino G., Di Marzo V. Two novel classes of neuroactive fatty acid amides are substrates for mouse neuroblastoma anandamide amidohydrolase. FEBS Lett. 377:1995;82-86.
46. Mechoulam R., Fride E., Hanus L., Sheskin T., Bisogno T., Di Marzo V., Bayewitch M., Vogel Z. Anandamide may mediate sleep induction. Nature. 389:1997;25-26.
47. Mechoulam R., Fride E., Di Marzo V. Endocannabinoids. Eur. J. Pharmacol. 359:1998;1-18.
48. Mendeslon W.B., Basile A.S. The hypnotic actions of oleamide are blocked by a cannabinoid receptor antagonist. Neuroreport. 10:1999;3237-3239.
49. Natarajan V., Schmid P.C., Reddy P.V., Schmid H.H.O. Catabolism of N-acylethanolamine phospholipids by dog brain preparations. J. Neurochem. 42:1984;1613-1619.
50. Paria B.C., Das S.K., Dey S.K. The preimplantation mouse embryo is a target for cannabinoid ligand-receptor signaling. Proc. Natl. Acad. Sci. USA. 92:1995;9460-9464.
51. Paria B.C., Song H., Wang X., Schmid P.C., Krebsbach R.J., Schmid H.H.O., Bonner T.I., Zimmer A., Dey S.K. Dysregulation of cannabinoid signaling disrupts uterine receptivity for embryo implantation. J. Biol. Chem. 276:2001;20523-20528.
52. Patricelli M.P., Cravatt B.F. Proteins regulating the biosynthesis and inactivation of neuromodulatory fatty acid amides. Vitam. Horm. 62:2001;95-131.
53. Patricelli M.P., Lashuel H.A., Giang D.K., Kelly J.W., Cravatt B.F. Comparative characterization of a wild type and transmembrane domain-deleted fatty acid amide hydrolase: identification of the transmembrane domain as a site for oligomerization. Biochemistry. 37:1998;15177-15187.
54. Patterson J.E., Ollman I.R., Cravatt B.F., Boger D.L., Wong C.-H., Lerner R.A. Inhibition of oleamide hydrolase catalyzed hydrolysis of the endogenous sleep-inducing lipid cis-9-octadecenamide. J. Am. Chem. Soc. 118:1996;5938-5945.
55. Piccinni M.P., Beloni L., Livi C., Maggi E., Scarselli G., Romagnani S. Defective production of both leukemia inhibitory factor and type 2 T-helper cytokines by decidual T cells in unexplained recurrent abortions. Nat. Med. 4:1998;1020-1024.
56. Piomelli D., Giuffrida A., Calignano A., Rodriguez de Fonseca F. The endocannabinoid system as a target for therapeutic drugs. Trends Pharmacol. Sci. 21:2000;218-224.
57. Pop E. Cannabinoids, endogenous ligands and synthetic analogs. Curr. Opin. Chem. Biol. 3:1999;418-425.
58. Puffenbarger R.A., Kapulina O., Howell J.M., Deutsch D.G. Characterization of the 5′-sequence of the mouse fatty acid amide hydrolase. Neurosci. Lett. 314:2001;21-24.
59. Rochefort H., Platet N., Hayshido Y., Derocq D., Lucas A., Cunat S., Garcia M. Estrogen receptor mediated inhibition of cancer cell invasion and motility: an overview. J. Steriod Biochem. Mol. Biol. 65:1998;163-168.
60. Rodriguez de Fonseca F., Carrera M., Navarro M., Koob G.F., Weiss F. Activation of corticotropin-releasing factor in the limbic system during cannabinoid withdrawal. Science. 276:1997;2050-2054.
61. Rodriguez de Fonseca F., Navarro M., Gomez R., Escuredo L., Nava F., Fu J., Murillo-Rodriguez E., Giuffrida A., LoVerme J., Gaetani S., Kathuria S., Gall C., Piomelli D. An anorexic lipid mediator regulated by feeding. Nature. 414:2001;209-212.
62. Romero J., Garcia-Palomero E., Lin S.Y., Ramos J.A., Makriyannis A., Fernandez-Ruiz J.J. Extrapyramidal effects of methanandamide, an analog of anandamide, the endogenous CB1 receptor ligand. Life Sci. 58:1996;1249-1257.
63. Romero J., Hillard C.J., Calero M., Rabano A. Fatty acid amide hydrolase localization in the human central nervous system: an immunohistochemical study. Brain Res. Mol. Brain Res. 100:2002;85-93.
64. Schmid P.C., Reddy P.V., Natarajan V., Schmid H.H.O. Metabolism of N-acylethanolamine phospholipids by a mammalian phosphodiesterase of the phospholipase D type. J. Biol. Chem. 258:1983;9302-9306.
65. Schmid P.C., Zuzarte-Augustin M.L., Schmid H.H.O. Properties of rat liver N-acylethanolamine amidohydrolase. J. Biol. Chem. 260:1985;14145-14149.
66. Shih J.C., Chen K., Ridd M.J. Monoamine oxidase: from genes to behavior. Annu. Rev. Neurosci. 22:1999;197-217.
67. Siegel G.J., Agranoff B.W., Albers R.W., Molinoff P.B. Basic Neurochemistry. 1994;Raven Press, New York.
68. Sipe J.C., Chiang K., Gerber A.L., Beutler E., Cravatt B.F. A missense mutation in human fatty acid amide hydrolase associated with problem drug use. Proc. Natl. Acad. Sci. USA. 99:2002;8394-8399.
69. Smith P.B., Compton D.R., Welch S.P., Razdan R.K., Mechoulam R., Martin B.R. The pharmacological activity of anandamide, a putative endogenous cannabinoid, in mice. J. Pharmacol. Exp. Ther. 270:1994;219-227.
70. Sorlie T., Perou C.M., Tibshirani R., Aas T., Geisler S., Johnsen H., Hastie T., Eisen M.B., van de Rijn M., Jeffrey S.S., Thorsen T., Quist H., Matese J.C., Brown P.O., Botstein D., Eystein Lonning P., Borresen-Dale A.L. Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications. Proc. Natl. Acad. Sci. USA. 98:2001;10869-10874.
71. Tanda G., Pontieri F.E., Di Chiara G. Cannabinoid and heroin activation of mesolimbic dopamine transmission by a common mu1 opioid receptor mechanism. Science. 276:1997;2048-2050.
72. Thomas E.A., Carson M.J., Neal M.J., Sutcliffe J.G. Unique allosteric regulation of 5-hydroxytryptamine receptor-mediated signal transduction by oleamide. Proc. Natl. Acad. Sci. USA. 94:1997;14115-14119.
73. Thompson E.W., Paik S., Brunner N., Sommers C.L., Zugmaier G., Clarke R., Shima T.B., Torri J., Donahue S., Lippman M.E., Martin G.R., Dickson R.B. Association of increased basement membrane invasiveness with absence of estrogen receptor and expression of vimentin in human breast cancer cell lines. J. Cell. Physiol. 150:1992;534-544.
74. Tsou K., Nogueron M.I., Muthian S., Sanudo-Pena M.C., Hillard C.J., Deutsch D.G., Walker J.M. Fatty acid amide hydrolase is located preferentially in large neurons in the rat central nervous system as revealed by immunohistochemistry. Neurosci. Lett. 254:1998;137-140.
75. Ueda N., Kurahashi Y., Yamamoto S., Tokunaga T. Partial purification and characterization of the porcine brain enzyme hydrolyzing and synthesizing anandamide. J. Biol. Chem. 270:1995;23823-23827.
76. Waleh N.S., Cravatt B.F., Apte-Deshpande A., Terao A., Kilduff T.S. Transcriptional regulation of the mouse fatty acid amide hydrolase gene. Gene. 291:2002;203-210.
77. Willoughby K.A., Moore S.F., Martin B.R., Ellis E.F. The biodisposition and metabolism of anandamide in mice. J. Pharmacol. Exp. Ther. 282:1997;243-247.
78. Wilson R.I., Nicoll R.A. Endocannabinoid signaling in the brain. Science. 296:2002;678-682.
79. Yost C.S., Hampson A.J., Leonoudakis D., Koblin D.D., Bornheim L.M., Gray A.T. Oleamide potentiates benzodiazepine-sensitive gamma-aminobutyric acid receptor activity but does not alter minimum alveolar anesthetic concentration. Anesth. Analg. 86:1998;1294-1300.
80. Zimmerman M. Pathobiology of neuropathic pain. Eur. J. Pharmacol. 429:2001;23-37.